[
  {
    "ts": "2026-02-23T10:30:00+00:00",
    "headline": "3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds",
    "summary": "Viking stock has plenty of room to run.",
    "url": "https://www.fool.com/investing/2026/02/23/3-reasons-viking-therapeutics-stock-could-10x/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "9dabe636-10b2-3921-929f-f0971dee2050",
      "content": {
        "id": "9dabe636-10b2-3921-929f-f0971dee2050",
        "contentType": "STORY",
        "title": "3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds",
        "description": "",
        "summary": "Viking stock has plenty of room to run.",
        "pubDate": "2026-02-23T10:30:00Z",
        "displayTime": "2026-02-23T10:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/40166dc06a1cc3bf0520a3b3dc811c96",
          "originalWidth": 1400,
          "originalHeight": 923,
          "caption": "A researcher works at a laptop in a lab.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8ms0ndEUmtXrFkkoECWj0w--~B/aD05MjM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/40166dc06a1cc3bf0520a3b3dc811c96.cf.webp",
              "width": 1400,
              "height": 923,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6DyizSm4MwCeb5llJR76Lg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/40166dc06a1cc3bf0520a3b3dc811c96.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/23/3-reasons-viking-therapeutics-stock-could-10x/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-reasons-viking-therapeutics-stock-103000062.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T10:11:20+00:00",
    "headline": "Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial",
    "summary": "COPENHAGEN, Feb 23 () - Novo Nordisk said on Monday its next-generation obesity drug CagriSema ‚Äåwas less effective than Eli Lilly's tirzepatide ‚Äåin a head-to-head trial, a setback in the race ‚Äãfor dominance in the weight-loss drug market. The trial was designed to show CagriSema was at least as effective as tirzepatide in reducing weight, but ‚Äåfailed to meet ‚Å†that goal, Novo said in a statement.",
    "url": "https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "7eb5501f-7c94-3163-8c4e-8412730553d9",
      "content": {
        "id": "7eb5501f-7c94-3163-8c4e-8412730553d9",
        "contentType": "STORY",
        "title": "Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial",
        "description": "",
        "summary": "COPENHAGEN, Feb 23 () - Novo Nordisk said on Monday its next-generation obesity drug CagriSema ‚Äåwas less effective than Eli Lilly's tirzepatide ‚Äåin a head-to-head trial, a setback in the race ‚Äãfor dominance in the weight-loss drug market. The trial was designed to show CagriSema was at least as effective as tirzepatide in reducing weight, but ‚Äåfailed to meet ‚Å†that goal, Novo said in a statement.",
        "pubDate": "2026-02-23T10:11:20Z",
        "displayTime": "2026-02-23T10:11:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7",
          "originalWidth": 800,
          "originalHeight": 572,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oBGYgL02vdNB3H_4k.SyNw--~B/aD01NzI7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7.cf.webp",
              "width": 800,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yW1zE99MZUHRvddOxzpIIg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:36:50+00:00",
    "headline": "Novo Nordisk Weight-Loss Drug Less Effective Than Eli Lilly's, Trial Data Shows",
    "summary": "Novo Nordisk (NVO) US-listed shares fell early Monday after the latest trial results of the Danish p",
    "url": "https://finance.yahoo.com/news/novo-nordisk-weight-loss-drug-113650789.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "a7adad91-791a-3260-81a9-d2c8ff1fd755",
      "content": {
        "id": "a7adad91-791a-3260-81a9-d2c8ff1fd755",
        "contentType": "STORY",
        "title": "Novo Nordisk Weight-Loss Drug Less Effective Than Eli Lilly's, Trial Data Shows",
        "description": "",
        "summary": "Novo Nordisk (NVO) US-listed shares fell early Monday after the latest trial results of the Danish p",
        "pubDate": "2026-02-23T11:36:50Z",
        "displayTime": "2026-02-23T11:36:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/mt_newswires_premium_news_706/f360f3dd1acd0991db5012422fc00211",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "novonordisk - Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eliLOTQZlBN.EI2msY8t5Q--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/mt_newswires_premium_news_706/f360f3dd1acd0991db5012422fc00211.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Wm42B1.q1CBU9m2gxaHtkw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/mt_newswires_premium_news_706/f360f3dd1acd0991db5012422fc00211.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-weight-loss-drug-113650789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-weight-loss-drug-113650789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:36:37+00:00",
    "headline": "Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Monday; Novo Nordisk, Strategy to Decline",
    "summary": "The most-talked-about stocks in the Reddit subforum Wallstreetbets were mostly lower hours before Mo",
    "url": "https://finance.yahoo.com/news/social-buzz-wallstreetbets-stocks-mostly-113637624.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "9fedea89-ba6c-3d18-bdc6-5b18e61d4744",
      "content": {
        "id": "9fedea89-ba6c-3d18-bdc6-5b18e61d4744",
        "contentType": "STORY",
        "title": "Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Monday; Novo Nordisk, Strategy to Decline",
        "description": "",
        "summary": "The most-talked-about stocks in the Reddit subforum Wallstreetbets were mostly lower hours before Mo",
        "pubDate": "2026-02-23T11:36:37Z",
        "displayTime": "2026-02-23T11:36:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/social-buzz-wallstreetbets-stocks-mostly-113637624.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/social-buzz-wallstreetbets-stocks-mostly-113637624.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "AM"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MSTR"
            },
            {
              "symbol": "HOOD"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "MSFT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:07:00+00:00",
    "headline": "Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Rival in Trial",
    "summary": "Shares fell sharply after the Danish drugmaker said its CagriSema experimental obesity drug failed to beat the weight loss delivered by Eli Lilly‚Äôs Zepbound in a head-to-head clinical trial.",
    "url": "https://www.wsj.com/health/pharma/novo-nordisk-shares-slide-after-obesity-drug-misses-key-goal-in-trial-263845ba?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "882d8a85-7d67-34a5-9359-3e21c423286a",
      "content": {
        "id": "882d8a85-7d67-34a5-9359-3e21c423286a",
        "contentType": "STORY",
        "title": "Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Rival in Trial",
        "description": "",
        "summary": "Shares fell sharply after the Danish drugmaker said its CagriSema experimental obesity drug failed to beat the weight loss delivered by Eli Lilly‚Äôs Zepbound in a head-to-head clinical trial.",
        "pubDate": "2026-02-23T11:07:00Z",
        "displayTime": "2026-02-23T11:07:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/882d8a85-7d67-34a5-9359-3e21c423286a/novo-nordisk-shares-plunge.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/1299d3fc5e2b731f491be8edaf27536d",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MyL48X4s4gpQWSdt3IrYQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/1299d3fc5e2b731f491be8edaf27536d.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmXDncVkC6u9q6z0TItpZg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/1299d3fc5e2b731f491be8edaf27536d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/novo-nordisk-shares-slide-after-obesity-drug-misses-key-goal-in-trial-263845ba?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T10:58:00+00:00",
    "headline": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Eli Lilly, Paramount, Nvidia, and More",
    "summary": "Nvidia shares tick up as investors await the chip maker‚Äôs fourth-quarter earnings, which likely will reveal how artificial-intelligence demand is holding up.",
    "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
      "content": {
        "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
        "contentType": "STORY",
        "title": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Eli Lilly, Paramount, Nvidia, and More",
        "description": "",
        "summary": "Nvidia shares tick up as investors await the chip maker‚Äôs fourth-quarter earnings, which likely will reveal how artificial-intelligence demand is holding up.",
        "pubDate": "2026-02-23T10:58:00Z",
        "displayTime": "2026-02-23T10:58:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f7d77d0b-860e-34ff-a495-c3fdff8b2514/these-stocks-are-today%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YpTBpBgno7NJFmEn4fooOg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SCGkZGeqjG9WPS36b0yD8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PSKY"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVDA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T10:56:49+00:00",
    "headline": "Podcast: Which pharma and medtech companies came out on top in 2025 revenues?",
    "summary": "The healthcare editorial teams discusses the key trends and growth drivers in companies' recent 2025 financial results.",
    "url": "https://www.pharmaceutical-technology.com/features/podcast-which-pharma-and-medtech-companies-came-out-on-top-in-2025-revenues/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "4c21b03b-ac35-3ab5-9dac-67690432c5c0",
      "content": {
        "id": "4c21b03b-ac35-3ab5-9dac-67690432c5c0",
        "contentType": "STORY",
        "title": "Podcast: Which pharma and medtech companies came out on top in 2025 revenues?",
        "description": "",
        "summary": "The healthcare editorial teams discusses the key trends and growth drivers in companies' recent 2025 financial results.",
        "pubDate": "2026-02-23T10:56:49Z",
        "displayTime": "2026-02-23T10:56:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/cecf72fe419727e27c4297cfdfb8724e",
          "originalWidth": 1000,
          "originalHeight": 377,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QpPJwBSei73InI9Ki9UVfg--~B/aD0zNzc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/cecf72fe419727e27c4297cfdfb8724e.cf.webp",
              "width": 1000,
              "height": 377,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/34PHKYhhEBdL8cBWzz97_w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/cecf72fe419727e27c4297cfdfb8724e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/features/podcast-which-pharma-and-medtech-companies-came-out-on-top-in-2025-revenues/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/podcast-pharma-medtech-companies-came-105649000.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "EW"
            },
            {
              "symbol": "MDT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T10:06:24+00:00",
    "headline": "Stocks to Watch Monday: Domino's Pizza, Novo Nordisk, Eli Lilly, Delta",
    "summary": "üîé American Airlines (AAL), Delta Air Lines (DAL) and United Airlines (UAL): A blizzard caused mass flight cancellations on the East Coast. More than 8,000 flights scheduled for Sunday and Monday had been canceled as of Sunday afternoon, according to FlightAware.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
      "content": {
        "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Domino's Pizza, Novo Nordisk, Eli Lilly, Delta",
        "description": "",
        "summary": "üîé American Airlines (AAL), Delta Air Lines (DAL) and United Airlines (UAL): A blizzard caused mass flight cancellations on the East Coast. More than 8,000 flights scheduled for Sunday and Monday had been canceled as of Sunday afternoon, according to FlightAware.",
        "pubDate": "2026-02-23T10:06:24Z",
        "displayTime": "2026-02-23T10:06:24Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cb781f9d-b9a5-3f5a-bfb4-b439b3b47382/stocks-to-watch-monday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KnlNOKh2C6QgkEmemrj6mg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zhLP7itajp.wiPUq1vzKdA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO.B"
            },
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "DAL"
            },
            {
              "symbol": "FBIN"
            },
            {
              "symbol": "AAL"
            },
            {
              "symbol": "UAL"
            },
            {
              "symbol": "D"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:59:38+00:00",
    "headline": "Novo Nordisk Dives As Next-Gen Obesity Drug Fails To Match Eli Lilly's Zepbound",
    "summary": "Novo Nordisk stock dived after Novo's next-generation obesity drug CagriSema didn't match weight loss from Eli Lilly's Zepbound. Lilly stock rose.",
    "url": "https://www.investors.com/news/technology/novo-nordisk-dives-next-gen-obesity-drug-fails-to-match-eli-lilly-zepbound/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "768f33a0-eb6d-3261-823c-4bb7c71825e8",
      "content": {
        "id": "768f33a0-eb6d-3261-823c-4bb7c71825e8",
        "contentType": "STORY",
        "title": "Novo Nordisk Dives As Next-Gen Obesity Drug Fails To Match Eli Lilly's Zepbound",
        "description": "",
        "summary": "Novo Nordisk stock dived after Novo's next-generation obesity drug CagriSema didn't match weight loss from Eli Lilly's Zepbound. Lilly stock rose.",
        "pubDate": "2026-02-23T12:59:38Z",
        "displayTime": "2026-02-23T12:59:38Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/768f33a0-eb6d-3261-823c-4bb7c71825e8/novo-nordisk-dives-as.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/5dcb64c0eaa4cddb85491e2fdb5e1d5f",
          "originalWidth": 1000,
          "originalHeight": 511,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ROtisKKZCPH047T1qbT2JQ--~B/aD01MTE7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/5dcb64c0eaa4cddb85491e2fdb5e1d5f.cf.webp",
              "width": 1000,
              "height": 511,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kZHoeLqHyXHi9aWRxqpbIw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/5dcb64c0eaa4cddb85491e2fdb5e1d5f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/novo-nordisk-dives-next-gen-obesity-drug-fails-to-match-eli-lilly-zepbound/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "GPCR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:39:06+00:00",
    "headline": "Novo Nordisk flags board members for re-election amid restructuring efforts",
    "summary": "Three new board and shareholder-elected members could join Novo‚Äôs council, which largely consists of recent appointees following a restructure in October 2025.",
    "url": "https://www.pharmaceutical-technology.com/news/novo-nordisk-board-shakeup-election-recommendations/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "2574fae0-1781-3486-bc4a-4e85119277e7",
      "content": {
        "id": "2574fae0-1781-3486-bc4a-4e85119277e7",
        "contentType": "STORY",
        "title": "Novo Nordisk flags board members for re-election amid restructuring efforts",
        "description": "",
        "summary": "Three new board and shareholder-elected members could join Novo‚Äôs council, which largely consists of recent appointees following a restructure in October 2025.",
        "pubDate": "2026-02-23T12:39:06Z",
        "displayTime": "2026-02-23T12:39:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/65120f4c2796e98f05dc97d112e4b3d6",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "Shareholders will determine the composition of Novo Nordisk's board in an Annual General Meeting on the 26 March. Credit: Below the Sky/Shutterstock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ySMzM4tODIOV7y_P0R3O7Q--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/65120f4c2796e98f05dc97d112e4b3d6.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DMI7l1Dr.8PjmJkLBHD2YQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/65120f4c2796e98f05dc97d112e4b3d6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/novo-nordisk-board-shakeup-election-recommendations/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-flags-board-members-123906245.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "GMAB"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "TAK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:38:00+00:00",
    "headline": "1 Reason I'm Seriously Considering Novo Nordisk as a Buy‚Äëand‚ÄëNever‚ÄëSell Obesity Stock",
    "summary": "Novo Nordisk investors get a second bite at the Ozempic apple.",
    "url": "https://www.fool.com/investing/2026/02/23/1-reason-im-seriously-considering-novo-nordisk/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "22c9983e-1e59-377d-86dc-119adf0e52eb",
      "content": {
        "id": "22c9983e-1e59-377d-86dc-119adf0e52eb",
        "contentType": "STORY",
        "title": "1 Reason I'm Seriously Considering Novo Nordisk as a Buy‚Äëand‚ÄëNever‚ÄëSell Obesity Stock",
        "description": "",
        "summary": "Novo Nordisk investors get a second bite at the Ozempic apple.",
        "pubDate": "2026-02-23T12:38:00Z",
        "displayTime": "2026-02-23T12:38:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/ffc38f11cb377c1103f672ac1cce2bbc",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "A person using a GLP-1 injector pen.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vkqbtsuiusy6b2MrKdaKlw--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/ffc38f11cb377c1103f672ac1cce2bbc.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kBRRw6b9b3ZaNUMosBwTXw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/ffc38f11cb377c1103f672ac1cce2bbc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/23/1-reason-im-seriously-considering-novo-nordisk/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-reason-im-seriously-considering-123800435.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:35:16+00:00",
    "headline": "Stocks Down Pre-Bell as Trump Raises Global Tariffs Following Supreme Court Ruling",
    "summary": "The benchmark US stock measures were tracking in the red before the opening bell Monday as President",
    "url": "https://finance.yahoo.com/news/stocks-down-pre-bell-trump-123516237.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "c72c4c07-0aa8-3182-af08-26f22d926db5",
      "content": {
        "id": "c72c4c07-0aa8-3182-af08-26f22d926db5",
        "contentType": "STORY",
        "title": "Stocks Down Pre-Bell as Trump Raises Global Tariffs Following Supreme Court Ruling",
        "description": "",
        "summary": "The benchmark US stock measures were tracking in the red before the opening bell Monday as President",
        "pubDate": "2026-02-23T12:35:16Z",
        "displayTime": "2026-02-23T12:35:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/mt_newswires_premium_news_706/8685121785649cec3dbcdbbd25333a86",
          "originalWidth": 1024,
          "originalHeight": 683,
          "caption": "wall street stock market flag new york trading equity - Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QVMgErJdOR7IkzCjRHm3pQ--~B/aD02ODM7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/mt_newswires_premium_news_706/8685121785649cec3dbcdbbd25333a86.cf.webp",
              "width": 1024,
              "height": 683,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dimQxOClk1isv1IKNf9JtA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/mt_newswires_premium_news_706/8685121785649cec3dbcdbbd25333a86.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/stocks-down-pre-bell-trump-123516237.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stocks-down-pre-bell-trump-123516237.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^DJI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:41:55+00:00",
    "headline": "Novo Nordisk's CagriSema trial deals a blow in obesity drug rivalry with Eli Lilly",
    "summary": "COPENHAGEN, Feb 23 () - Novo Nordisk's next-generation obesity drug CagriSema was less effective than Eli Lilly's tirzepatide in a head-to-head trial, the Danish drugmaker said on Monday, in a setback to its ‚Äåefforts to dominate the weight-loss market. Novo Nordisk is fighting to regain first-mover advantage in the obesity ‚Äåtreatment market, where demand for drugs with higher efficacy has surged.",
    "url": "https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "7eb5501f-7c94-3163-8c4e-8412730553d9",
      "content": {
        "id": "7eb5501f-7c94-3163-8c4e-8412730553d9",
        "contentType": "STORY",
        "title": "Novo Nordisk's CagriSema trial deals a blow in obesity drug rivalry with Eli Lilly",
        "description": "",
        "summary": "COPENHAGEN, Feb 23 () - Novo Nordisk's next-generation obesity drug CagriSema was less effective than Eli Lilly's tirzepatide in a head-to-head trial, the Danish drugmaker said on Monday, in a setback to its ‚Äåefforts to dominate the weight-loss market. Novo Nordisk is fighting to regain first-mover advantage in the obesity ‚Äåtreatment market, where demand for drugs with higher efficacy has surged.",
        "pubDate": "2026-02-23T11:41:55Z",
        "displayTime": "2026-02-23T11:41:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7",
          "originalWidth": 800,
          "originalHeight": 572,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oBGYgL02vdNB3H_4k.SyNw--~B/aD01NzI7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7.cf.webp",
              "width": 800,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yW1zE99MZUHRvddOxzpIIg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:32:02+00:00",
    "headline": "Stocks to Watch Monday: Domino's Pizza, Eli Lilly, Merck, Gilead",
    "summary": "‚ÜóÔ∏è Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. Shares rose roughly 1.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
      "content": {
        "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Domino's Pizza, Eli Lilly, Merck, Gilead",
        "description": "",
        "summary": "‚ÜóÔ∏è Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. Shares rose roughly 1.",
        "pubDate": "2026-02-23T11:32:02Z",
        "displayTime": "2026-02-23T11:32:02Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cb781f9d-b9a5-3f5a-bfb4-b439b3b47382/stocks-to-watch-monday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KnlNOKh2C6QgkEmemrj6mg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zhLP7itajp.wiPUq1vzKdA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NOVO.B"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "AAL"
            },
            {
              "symbol": "DAL"
            },
            {
              "symbol": "UAL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:45:58+00:00",
    "headline": "Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin",
    "summary": "Novo Nordisk stock plunged Monday after the drugmaker said its obesity shot, CagriSema, proved less effective than Lilly's tirzepatide.",
    "url": "https://www.investors.com/news/technology/novo-nordisk-dives-next-gen-obesity-drug-fails-to-match-eli-lilly-zepbound/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "768f33a0-eb6d-3261-823c-4bb7c71825e8",
      "content": {
        "id": "768f33a0-eb6d-3261-823c-4bb7c71825e8",
        "contentType": "STORY",
        "title": "Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin",
        "description": "",
        "summary": "Novo Nordisk stock plunged Monday after the drugmaker said its obesity shot, CagriSema, proved less effective than Lilly's tirzepatide.",
        "pubDate": "2026-02-23T14:45:58Z",
        "displayTime": "2026-02-23T14:45:58Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/768f33a0-eb6d-3261-823c-4bb7c71825e8/novo-nordisk-dives-as.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/5dcb64c0eaa4cddb85491e2fdb5e1d5f",
          "originalWidth": 1000,
          "originalHeight": 511,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ROtisKKZCPH047T1qbT2JQ--~B/aD01MTE7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/5dcb64c0eaa4cddb85491e2fdb5e1d5f.cf.webp",
              "width": 1000,
              "height": 511,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kZHoeLqHyXHi9aWRxqpbIw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/5dcb64c0eaa4cddb85491e2fdb5e1d5f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/novo-nordisk-dives-next-gen-obesity-drug-fails-to-match-eli-lilly-zepbound/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "GPCR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:41:07+00:00",
    "headline": "Stocks to Watch Monday: Novo Nordisk, Merck, Domino's, Gilead",
    "summary": "üîé Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. ‚ÜòÔ∏è Novo Nordisk (NVO), (DK:NOVO.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
      "content": {
        "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Novo Nordisk, Merck, Domino's, Gilead",
        "description": "",
        "summary": "üîé Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. ‚ÜòÔ∏è Novo Nordisk (NVO), (DK:NOVO.",
        "pubDate": "2026-02-23T14:41:07Z",
        "displayTime": "2026-02-23T14:41:07Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cb781f9d-b9a5-3f5a-bfb4-b439b3b47382/stocks-to-watch-monday-novo.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KnlNOKh2C6QgkEmemrj6mg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zhLP7itajp.wiPUq1vzKdA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NOVO.B"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "FBIN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:30:58+00:00",
    "headline": "Instant View: Novo's CagriSema setback may shift investor focus to M&A strategy, analysts say",
    "summary": "Feb 23 () - Novo Nordisk's next-generation weight-loss drug CagriSema was less effective than Eli Lilly's Zepbound in a head-to-head trial, a fresh blow to the Danish drugmaker's efforts to reclaim its early lead in the booming ‚Äåobesity drug market. Below are some reactions from analysts.",
    "url": "https://finance.yahoo.com/news/novos-cagrisema-setback-may-shift-142956039.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "f0d1e90e-1c2e-3c09-b509-d2e18f45d60b",
      "content": {
        "id": "f0d1e90e-1c2e-3c09-b509-d2e18f45d60b",
        "contentType": "STORY",
        "title": "Instant View: Novo's CagriSema setback may shift investor focus to M&A strategy, analysts say",
        "description": "",
        "summary": "Feb 23 () - Novo Nordisk's next-generation weight-loss drug CagriSema was less effective than Eli Lilly's Zepbound in a head-to-head trial, a fresh blow to the Danish drugmaker's efforts to reclaim its early lead in the booming ‚Äåobesity drug market. Below are some reactions from analysts.",
        "pubDate": "2026-02-23T14:30:58Z",
        "displayTime": "2026-02-23T14:30:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/4682edd01f225626d868e144ad2fba23",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "FILE PHOTO: The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/coUXq4i09F1MkVwResIldQ--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/4682edd01f225626d868e144ad2fba23.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IFvRfL5jPUjXJcPrydAOJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/4682edd01f225626d868e144ad2fba23.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novos-cagrisema-setback-may-shift-142956039.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novos-cagrisema-setback-may-shift-142956039.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:11:08+00:00",
    "headline": "Weight-loss drug trial results wipe ¬£147bn off Ozempic maker",
    "summary": "Almost ¬£150bn has been wiped off Ozempic drugmaker Novo Nordisk after a trial of its new weight-loss drug fell short of expectations.",
    "url": "https://uk.finance.yahoo.com/news/weight-loss-drug-trial-results-141108781.html",
    "source": "The Telegraph",
    "provider": "yfinance",
    "raw": {
      "id": "518585eb-8938-388e-93d1-42f16794bdc5",
      "content": {
        "id": "518585eb-8938-388e-93d1-42f16794bdc5",
        "contentType": "STORY",
        "title": "Weight-loss drug trial results wipe ¬£147bn off Ozempic maker",
        "description": "",
        "summary": "Almost ¬£150bn has been wiped off Ozempic drugmaker Novo Nordisk after a trial of its new weight-loss drug fell short of expectations.",
        "pubDate": "2026-02-23T14:11:08Z",
        "displayTime": "2026-02-23T14:11:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_telegraph_818/2c79a69293997315057919a9dce6d429",
          "originalWidth": 2500,
          "originalHeight": 1563,
          "caption": "A pharmacist displays boxes of Ozempic",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vMCwfGLoO2UyX6d7ZKFeaw--~B/aD0xNTYzO3c9MjUwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/the_telegraph_818/2c79a69293997315057919a9dce6d429.cf.webp",
              "width": 2500,
              "height": 1563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yYEKcmkY3MYuWPwtvtWbZg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_telegraph_818/2c79a69293997315057919a9dce6d429.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Telegraph",
          "url": "http://www.telegraph.co.uk/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/weight-loss-drug-trial-results-141108781.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/weight-loss-drug-trial-results-141108781.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:03:58+00:00",
    "headline": "Lilly to launch multi-dose weight-loss drug device in US",
    "summary": "Feb 23 () - Eli Lilly said on Monday it received the U. Food and ‚ÄåDrug Administration's approval to launch a ‚Äåfour-dose KwikPen for its weight-loss drug Zepbound, delivering a ‚Äãfull month of the treatment in a single device.",
    "url": "https://finance.yahoo.com/news/lilly-launch-multi-dose-weight-140358508.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "4be0cadf-d29a-3a57-a149-36127e97eccd",
      "content": {
        "id": "4be0cadf-d29a-3a57-a149-36127e97eccd",
        "contentType": "STORY",
        "title": "Lilly to launch multi-dose weight-loss drug device in US",
        "description": "",
        "summary": "Feb 23 () - Eli Lilly said on Monday it received the U. Food and ‚ÄåDrug Administration's approval to launch a ‚Äåfour-dose KwikPen for its weight-loss drug Zepbound, delivering a ‚Äãfull month of the treatment in a single device.",
        "pubDate": "2026-02-23T14:03:58Z",
        "displayTime": "2026-02-23T14:03:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/662ae5af29f9ed4e31924546092975fd",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rbBbJ4XtXhyrRBspR5VgXw--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/662ae5af29f9ed4e31924546092975fd.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NvWObtXyGjKJMhRxVDVdKg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/662ae5af29f9ed4e31924546092975fd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-launch-multi-dose-weight-140358508.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-launch-multi-dose-weight-140358508.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:00:00+00:00",
    "headline": "Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound¬Æ (tirzepatide) to include the four-dose single-patient use KwikPen¬Æ that delivers a full month of treatment in one device. With the Zepbound KwikPen, Lilly is expanding choice and helping ensure patients and healthcare providers can select the option that best fits individual needs, preferences, and circumstances. Patients, with a valid prescription, opting for se",
    "url": "https://finance.yahoo.com/news/zepbound-tirzepatide-most-prescribed-weight-140000762.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "291382bf-f293-3060-a091-2251efa87cca",
      "content": {
        "id": "291382bf-f293-3060-a091-2251efa87cca",
        "contentType": "STORY",
        "title": "Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound¬Æ (tirzepatide) to include the four-dose single-patient use KwikPen¬Æ that delivers a full month of treatment in one device. With the Zepbound KwikPen, Lilly is expanding choice and helping ensure patients and healthcare providers can select the option that best fits individual needs, preferences, and circumstances. Patients, with a valid prescription, opting for se",
        "pubDate": "2026-02-23T14:00:00Z",
        "displayTime": "2026-02-23T14:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zepbound-tirzepatide-most-prescribed-weight-140000762.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zepbound-tirzepatide-most-prescribed-weight-140000762.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T13:41:13+00:00",
    "headline": "Novo Nordisk's CagriSema falls short against Eli Lilly's in trial",
    "summary": "<body><p>STORY: In a head-to-head trial, Novo Nordisk said its next-generation obesity drug CagriSema was less effective than Eli Lilly's&nbsp;tirzepatide.</p><p>It's a setback for the firm in the race for dominance in the weight-loss drug market.</p><p>The trial was designed to show CagriSema was at least as effective as tirzepatide in reducing weight.</p><p>But Novo Nordisk said in a statement that it failed to meet that goal.</p><p>Its share price fell as much as&nbsp; 11% by mid-morning trade on Monday.</p><p>The results mean Novo's next-generation treatment delivered less weight loss than Eli Lilly's drug, which is already on the market under the brand name Zepbound and Mounjaro.</p><p>Novo Nordisk said additional trials are exploring the full weight loss potential of CagriSema.</p><p>And include&nbsp;higher-dose combinations.</p><p>Eli Lilly shares rose 4% in U.S. premarket trading.</p></body>",
    "url": "https://finance.yahoo.com/video/novo-nordisks-cagrisema-falls-short-134113322.html",
    "source": "Reuters Videos",
    "provider": "yfinance",
    "raw": {
      "id": "c11983dd-0c8f-3e12-947d-e3b7e0c6939b",
      "content": {
        "id": "c11983dd-0c8f-3e12-947d-e3b7e0c6939b",
        "contentType": "VIDEO",
        "title": "Novo Nordisk's CagriSema falls short against Eli Lilly's in trial",
        "description": "<title><body><p>STORY: In a head-to-head trial, Novo Nordisk said its next-generation obesity drug CagriSema was less effective than Eli Lilly's¬†tirzepatide.</p><p>It's a setback for the firm in the race for dominance in the weight-loss drug market.</p><p>The trial was designed to show CagriSema was at least as effective as tirzepatide in reducing weight.</p><p>But Novo Nordisk said in a statement that it failed to meet that goal.</p><p>Its share price fell as much as¬† 11% by mid-morning trade on Monday.</p><p>The results mean Novo's next-generation treatment delivered less weight loss than Eli Lilly's drug, which is already on the market under the brand name Zepbound and Mounjaro.</p><p>Novo Nordisk said additional trials are exploring the full weight loss potential of CagriSema.</p><p>And include¬†higher-dose combinations.</p><p>Eli Lilly shares rose 4% in U.S. premarket trading.</p></body></title>",
        "summary": "<body><p>STORY: In a head-to-head trial, Novo Nordisk said its next-generation obesity drug CagriSema was less effective than Eli Lilly's&nbsp;tirzepatide.</p><p>It's a setback for the firm in the race for dominance in the weight-loss drug market.</p><p>The trial was designed to show CagriSema was at least as effective as tirzepatide in reducing weight.</p><p>But Novo Nordisk said in a statement that it failed to meet that goal.</p><p>Its share price fell as much as&nbsp; 11% by mid-morning trade on Monday.</p><p>The results mean Novo's next-generation treatment delivered less weight loss than Eli Lilly's drug, which is already on the market under the brand name Zepbound and Mounjaro.</p><p>Novo Nordisk said additional trials are exploring the full weight loss potential of CagriSema.</p><p>And include&nbsp;higher-dose combinations.</p><p>Eli Lilly shares rose 4% in U.S. premarket trading.</p></body>",
        "pubDate": "2026-02-23T13:41:13Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/uu/api/res/1.2/AfJFYDegnRSrrPvEkltUTA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/2b6adc23-eabc-4951-bccf-cd1c18f23102/main/1280x720/27s530ms/match/image.jpg",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aoqd2xfppRLjjKTjgnu9.g--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/2b6adc23-eabc-4951-bccf-cd1c18f23102/main/1280x720/27s530ms/match/image.jpg.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_jHMgv2iJOYLOR0CAU7Zhg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/2b6adc23-eabc-4951-bccf-cd1c18f23102/main/1280x720/27s530ms/match/image.jpg.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters Videos",
          "url": "http://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/novo-nordisks-cagrisema-falls-short-134113322.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/novo-nordisks-cagrisema-falls-short-134113322.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T13:19:45+00:00",
    "headline": "Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly",
    "summary": "COPENHAGEN, Feb 23 (Reuters) - Novo Nordisk's next-generation obesity drug CagriSema underperformed rival Eli Lilly's Zepbound in a head-to-head trial, the Danish drugmaker said on Monday, as it suffered a setback in its fight to ‚Äåregain leadership of the weight-loss market. Few analysts had predicted CagriSema would be found to be less effective than Lilly's drug that ‚Äåsells as Zepbound in the U.",
    "url": "https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "7eb5501f-7c94-3163-8c4e-8412730553d9",
      "content": {
        "id": "7eb5501f-7c94-3163-8c4e-8412730553d9",
        "contentType": "STORY",
        "title": "Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly",
        "description": "",
        "summary": "COPENHAGEN, Feb 23 (Reuters) - Novo Nordisk's next-generation obesity drug CagriSema underperformed rival Eli Lilly's Zepbound in a head-to-head trial, the Danish drugmaker said on Monday, as it suffered a setback in its fight to ‚Äåregain leadership of the weight-loss market. Few analysts had predicted CagriSema would be found to be less effective than Lilly's drug that ‚Äåsells as Zepbound in the U.",
        "pubDate": "2026-02-23T13:19:45Z",
        "displayTime": "2026-02-23T13:19:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7",
          "originalWidth": 800,
          "originalHeight": 572,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oBGYgL02vdNB3H_4k.SyNw--~B/aD01NzI7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7.cf.webp",
              "width": 800,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yW1zE99MZUHRvddOxzpIIg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T13:09:00+00:00",
    "headline": "Novo Nordisk's next obesity drug falls short of Lilly rival, wiping billions off its market value",
    "summary": "Novo Nordisk (NYSE:NVO) attempt to reclaim the initiative in the obesity drug race has backfired, after its experimental next-generation treatment failed to prove it was as effective as a rival therapy from Eli Lilly. The Danish drugmaker's shares were off 14% ahead of the bell in the US (it...",
    "url": "https://www.proactiveinvestors.com/companies/news/1087772/novo-nordisk-s-next-obesity-drug-falls-short-of-lilly-rival-wiping-billions-off-its-market-value-1087772.html",
    "source": "Proactive",
    "provider": "yfinance",
    "raw": {
      "id": "a2b9eb86-65a4-3b2c-b64a-a5eb2a25756c",
      "content": {
        "id": "a2b9eb86-65a4-3b2c-b64a-a5eb2a25756c",
        "contentType": "STORY",
        "title": "Novo Nordisk's next obesity drug falls short of Lilly rival, wiping billions off its market value",
        "description": "",
        "summary": "Novo Nordisk (NYSE:NVO) attempt to reclaim the initiative in the obesity drug race has backfired, after its experimental next-generation treatment failed to prove it was as effective as a rival therapy from Eli Lilly. The Danish drugmaker's shares were off 14% ahead of the bell in the US (it...",
        "pubDate": "2026-02-23T13:09:00Z",
        "displayTime": "2026-02-23T13:09:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/proactive_us_504/ab43de6574e9ab54523a12fea0e62e4f",
          "originalWidth": 960,
          "originalHeight": 720,
          "caption": "Novo Nordisk's next obesity drug falls short of Lilly rival, wiping billions off its market value",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2MGsktLslXmUr01bDG8rlQ--~B/aD03MjA7dz05NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/proactive_us_504/ab43de6574e9ab54523a12fea0e62e4f.cf.webp",
              "width": 960,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_hiRFqZq8DZPLN0cuZV9dA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/proactive_us_504/ab43de6574e9ab54523a12fea0e62e4f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Proactive",
          "url": "https://www.proactiveinvestors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.proactiveinvestors.com/companies/news/1087772/novo-nordisk-s-next-obesity-drug-falls-short-of-lilly-rival-wiping-billions-off-its-market-value-1087772.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-next-obesity-drug-130900424.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T13:06:00+00:00",
    "headline": "Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound",
    "summary": "The CagriSema study results are a setback for the Danish drugmaker in its efforts to regain ground lost to Eli Lilly in the obesity-drug market.",
    "url": "https://www.wsj.com/health/pharma/novo-nordisk-shares-slide-after-obesity-drug-misses-key-goal-in-trial-263845ba?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "882d8a85-7d67-34a5-9359-3e21c423286a",
      "content": {
        "id": "882d8a85-7d67-34a5-9359-3e21c423286a",
        "contentType": "STORY",
        "title": "Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound",
        "description": "",
        "summary": "The CagriSema study results are a setback for the Danish drugmaker in its efforts to regain ground lost to Eli Lilly in the obesity-drug market.",
        "pubDate": "2026-02-23T13:06:00Z",
        "displayTime": "2026-02-23T13:06:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/882d8a85-7d67-34a5-9359-3e21c423286a/novo-nordisk-shares-plunge.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/1299d3fc5e2b731f491be8edaf27536d",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MyL48X4s4gpQWSdt3IrYQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/1299d3fc5e2b731f491be8edaf27536d.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmXDncVkC6u9q6z0TItpZg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/1299d3fc5e2b731f491be8edaf27536d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/novo-nordisk-shares-slide-after-obesity-drug-misses-key-goal-in-trial-263845ba?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:17:00+00:00",
    "headline": "Novo Nordisk Stock Plunges and Eli Lilly Jumps. It‚Äôs All Down to This Weight-Loss Drug Trial.",
    "summary": "Novo shares slump after the Danish drugmaker‚Äôs experimental obesity drug fails to beat Lilly‚Äôs treatment in an 84-week trial.",
    "url": "https://www.barrons.com/articles/novo-nordisk-stock-eli-lilly-weight-loss-8715ba80?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "ade99e02-f1c5-3f9a-9d80-378a146f1a58",
      "content": {
        "id": "ade99e02-f1c5-3f9a-9d80-378a146f1a58",
        "contentType": "STORY",
        "title": "Novo Nordisk Stock Plunges and Eli Lilly Jumps. It‚Äôs All Down to This Weight-Loss Drug Trial.",
        "description": "",
        "summary": "Novo shares slump after the Danish drugmaker‚Äôs experimental obesity drug fails to beat Lilly‚Äôs treatment in an 84-week trial.",
        "pubDate": "2026-02-23T12:17:00Z",
        "displayTime": "2026-02-23T12:17:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ade99e02-f1c5-3f9a-9d80-378a146f1a58/novo-nordisk-stock-plunges.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/26KOn6oaSzam4fyehZ4clw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/phkijlebsiYXfKV4N8Qtzw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-stock-eli-lilly-weight-loss-8715ba80?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:39:00+00:00",
    "headline": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Eli Lilly, Arcellx, Paramount, Domino‚Äôs Pizza, Nvidia, and More",
    "summary": "Nvidia shares tick up as investors await the chip maker‚Äôs fourth-quarter earnings, which likely will reveal how artificial-intelligence demand is holding up.",
    "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
      "content": {
        "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
        "contentType": "STORY",
        "title": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Eli Lilly, Arcellx, Paramount, Domino‚Äôs Pizza, Nvidia, and More",
        "description": "",
        "summary": "Nvidia shares tick up as investors await the chip maker‚Äôs fourth-quarter earnings, which likely will reveal how artificial-intelligence demand is holding up.",
        "pubDate": "2026-02-23T11:39:00Z",
        "displayTime": "2026-02-23T11:39:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f7d77d0b-860e-34ff-a495-c3fdff8b2514/these-stocks-are-today%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YpTBpBgno7NJFmEn4fooOg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SCGkZGeqjG9WPS36b0yD8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PSKY"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "NVDA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:36:00+00:00",
    "headline": "Why Novo Nordisk Stock Is Pluging‚Äîand Why It‚Äôs Good News for Lilly",
    "summary": "Novo shares slump after the Danish drugmaker‚Äôs experimental obesity drug fails to beat Lilly‚Äôs treatment in an 84-week trial.",
    "url": "https://www.barrons.com/articles/novo-nordisk-stock-price-eli-lilly-drug-trial-8715ba80?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "ade99e02-f1c5-3f9a-9d80-378a146f1a58",
      "content": {
        "id": "ade99e02-f1c5-3f9a-9d80-378a146f1a58",
        "contentType": "STORY",
        "title": "Why Novo Nordisk Stock Is Pluging‚Äîand Why It‚Äôs Good News for Lilly",
        "description": "",
        "summary": "Novo shares slump after the Danish drugmaker‚Äôs experimental obesity drug fails to beat Lilly‚Äôs treatment in an 84-week trial.",
        "pubDate": "2026-02-23T14:36:00Z",
        "displayTime": "2026-02-23T14:36:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ade99e02-f1c5-3f9a-9d80-378a146f1a58/why-novo-nordisk-stock-is.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/26KOn6oaSzam4fyehZ4clw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/phkijlebsiYXfKV4N8Qtzw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-stock-price-eli-lilly-drug-trial-8715ba80?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:11:08+00:00",
    "headline": "Weight-loss drug trial results wipe ¬£147bn off Ozempic maker",
    "summary": "Almost ¬£150bn has been wiped off Ozempic drugmaker Novo Nordisk after a trial of its new weight-loss drug fell short of expectations.",
    "url": "https://www.telegraph.co.uk/business/2026/02/23/almost-150bn-wiped-off-ozempic-maker/",
    "source": "The Telegraph",
    "provider": "yfinance",
    "raw": {
      "id": "b5219425-d18d-37a8-abdc-89820545c171",
      "content": {
        "id": "b5219425-d18d-37a8-abdc-89820545c171",
        "contentType": "STORY",
        "title": "Weight-loss drug trial results wipe ¬£147bn off Ozempic maker",
        "description": "",
        "summary": "Almost ¬£150bn has been wiped off Ozempic drugmaker Novo Nordisk after a trial of its new weight-loss drug fell short of expectations.",
        "pubDate": "2026-02-23T14:11:08Z",
        "displayTime": "2026-02-23T14:11:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_telegraph_258/2c79a69293997315057919a9dce6d429",
          "originalWidth": 2500,
          "originalHeight": 1563,
          "caption": "A pharmacist displays boxes of Ozempic",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ALin_3Im9r_Pv45XONE3YA--~B/aD0xNTYzO3c9MjUwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/the_telegraph_258/2c79a69293997315057919a9dce6d429.cf.webp",
              "width": 2500,
              "height": 1563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rzFrufKBs9U2YaWNUs5_fw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_telegraph_258/2c79a69293997315057919a9dce6d429.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Telegraph",
          "url": "http://www.telegraph.co.uk/"
        },
        "canonicalUrl": {
          "url": "https://www.telegraph.co.uk/business/2026/02/23/almost-150bn-wiped-off-ozempic-maker/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/weight-loss-drug-trial-results-141108858.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:07:00+00:00",
    "headline": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Lilly, Arcellx, Domino‚Äôs, United Airlines, International Paper, Strategy, and More",
    "summary": "Novo Nordisk stock sinks after new trial data show weight-loss drug candidate CagriSema is less effective than a rival treatment from Eli Lilly.",
    "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
      "content": {
        "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
        "contentType": "STORY",
        "title": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Lilly, Arcellx, Domino‚Äôs, United Airlines, International Paper, Strategy, and More",
        "description": "",
        "summary": "Novo Nordisk stock sinks after new trial data show weight-loss drug candidate CagriSema is less effective than a rival treatment from Eli Lilly.",
        "pubDate": "2026-02-23T14:07:00Z",
        "displayTime": "2026-02-23T14:07:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f7d77d0b-860e-34ff-a495-c3fdff8b2514/these-stocks-are-today%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YpTBpBgno7NJFmEn4fooOg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SCGkZGeqjG9WPS36b0yD8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PSKY"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "IP"
            },
            {
              "symbol": "MSTR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T16:15:21+00:00",
    "headline": "Trump puts pressure on Netflix board, Domino's stock rises on Q4",
    "summary": "Yahoo Finance Senior Reporter Brooke DiPalma tracks several of the day's top trending stock tickers, including Variety reporting that Paramount Skydance (PSKY) plans to up its bid for Warner Bros. Discovery (WBD) while President Trump puts pressure on Netflix (NFLX) to fire his former US ambassador and national security advisor, Susan Rice, from the streaming giant's board. Novo Nordisk (NVO) stock is falling on Monday after its weight-loss drug underperformed compared to Eli Lilly's own GLP-1 in a clinical trial. And, Domino's Pizza (DPZ) shares getting a lift higher when the chain topped fourth quarter revenue estimates. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Market Catalysts.",
    "url": "https://finance.yahoo.com/video/trump-puts-pressure-netflix-board-161521046.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "d086c06e-ced2-3654-86cc-6e054503a1e3",
      "content": {
        "id": "d086c06e-ced2-3654-86cc-6e054503a1e3",
        "contentType": "VIDEO",
        "title": "Trump puts pressure on Netflix board, Domino's stock rises on Q4",
        "description": "<p>Yahoo Finance Senior Reporter <a data-i13n=\"cpos:1;pos:1\" href=\"https://www.yahoo.com/author/brooke-dipalma/\">Brooke DiPalma</a> tracks several of the day's top trending stock tickers, including <a data-i13n=\"cpos:2;pos:1\" href=\"https://variety.com/2026/film/news/paramount-warner-bros-discovery-higher-bid-will-netflix-walk-away-1236670140/\">Variety reporting</a> that Paramount Skydance (<a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/PSKY\">PSKY</a>) plans to up its bid for Warner Bros. Discovery (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/WBD\">WBD</a>) while President Trump puts pressure on Netflix (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/NFLX\">NFLX</a>) to fire his former US ambassador and national security advisor, Susan Rice, from the streaming giant's board.</p>\n<p>Novo Nordisk (<a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/quote/NVO\">NVO</a>) stock is falling on Monday after its weight-loss drug underperformed compared to Eli Lilly's own GLP-1 in a clinical trial.</p>\n<p>And, Domino's Pizza (<a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/quote/DPZ\">DPZ</a>) shares getting a lift higher when the chain topped fourth quarter revenue estimates.</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more¬†<a data-i13n=\"cpos:8;pos:1\" href=\"https://finance.yahoo.com/videos/series/market-catalysts/\">Market Catalysts</a>.</p>",
        "summary": "Yahoo Finance Senior Reporter Brooke DiPalma tracks several of the day's top trending stock tickers, including Variety reporting that Paramount Skydance (PSKY) plans to up its bid for Warner Bros. Discovery (WBD) while President Trump puts pressure on Netflix (NFLX) to fire his former US ambassador and national security advisor, Susan Rice, from the streaming giant's board. Novo Nordisk (NVO) stock is falling on Monday after its weight-loss drug underperformed compared to Eli Lilly's own GLP-1 in a clinical trial. And, Domino's Pizza (DPZ) shares getting a lift higher when the chain topped fourth quarter revenue estimates. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Market Catalysts.",
        "pubDate": "2026-02-23T16:15:21Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2026-02/a9b5b330-10d2-11f1-bf6e-0b64edec3636",
          "originalWidth": 8179,
          "originalHeight": 4605,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zo4vQaBSkj0SDyOUNBCgRA--~B/aD00NjA1O3c9ODE3OTthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-02/a9b5b330-10d2-11f1-bf6e-0b64edec3636.cf.webp",
              "width": 8179,
              "height": 4605,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lf8p29qjfM3LKYWZCn6Q6Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2026-02/a9b5b330-10d2-11f1-bf6e-0b64edec3636.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/trump-puts-pressure-netflix-board-161521046.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/trump-puts-pressure-netflix-board-161521046.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "WBD"
            },
            {
              "symbol": "NFLX"
            },
            {
              "symbol": "PSKY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T16:55:09+00:00",
    "headline": "Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out",
    "summary": "Feb 23 () - Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining ‚Äågains brought by its blockbuster weight-loss drug Wegovy, ‚Äåafter the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's ‚Äãrival. Novo, which in 2024 was worth more than $650 billion, has since shed around $475 billion, with the shares back at levels last seen before Wegovy transformed it into Europe's most ‚Äåvaluable drugmaker.",
    "url": "https://finance.yahoo.com/news/novo-nordisks-475-billion-rise-165509914.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "e6200641-1661-302c-af58-986a30e9501e",
      "content": {
        "id": "e6200641-1661-302c-af58-986a30e9501e",
        "contentType": "STORY",
        "title": "Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out",
        "description": "",
        "summary": "Feb 23 () - Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining ‚Äågains brought by its blockbuster weight-loss drug Wegovy, ‚Äåafter the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's ‚Äãrival. Novo, which in 2024 was worth more than $650 billion, has since shed around $475 billion, with the shares back at levels last seen before Wegovy transformed it into Europe's most ‚Äåvaluable drugmaker.",
        "pubDate": "2026-02-23T16:55:09Z",
        "displayTime": "2026-02-23T16:55:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/a075817c163ee72586baea1e41f68cec",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "Novo Nordisk logo and decreasing stock graph are seen in this illustration taken August 5, 2025. REUTERS/Dado Ruvic/Illustration",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ariLHLDvDF6uTtsxpkT.aA--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/a075817c163ee72586baea1e41f68cec.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cIq.nZj9rvpT7htGzt80vg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/a075817c163ee72586baea1e41f68cec.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-475-billion-rise-165509914.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-475-billion-rise-165509914.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T16:16:00+00:00",
    "headline": "Top Midday Stories: Novo Obesity Drug Doesn't Meet Primary Endpoint, Stock Falls; Gilead to Acquire Arcellx for $7.8 Billion",
    "summary": "All three major US stock indexes were down in late-morning trading Monday, as investors weigh the co",
    "url": "https://finance.yahoo.com/news/top-midday-stories-novo-obesity-161600151.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "66575aac-2f77-37e7-b76f-213bb003012b",
      "content": {
        "id": "66575aac-2f77-37e7-b76f-213bb003012b",
        "contentType": "STORY",
        "title": "Top Midday Stories: Novo Obesity Drug Doesn't Meet Primary Endpoint, Stock Falls; Gilead to Acquire Arcellx for $7.8 Billion",
        "description": "",
        "summary": "All three major US stock indexes were down in late-morning trading Monday, as investors weigh the co",
        "pubDate": "2026-02-23T16:16:00Z",
        "displayTime": "2026-02-23T16:16:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/top-midday-stories-novo-obesity-161600151.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-midday-stories-novo-obesity-161600151.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T16:15:40+00:00",
    "headline": "Why Eli Lilly Stock Just Popped",
    "summary": "Eli Lilly has some good news for investors today. Novo Nordisk has some bad news (which is also good news for Lilly).",
    "url": "https://www.fool.com/investing/2026/02/23/why-eli-lilly-stock-just-popped/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "c737d9bc-83fd-3ed4-abbe-b8200992682b",
      "content": {
        "id": "c737d9bc-83fd-3ed4-abbe-b8200992682b",
        "contentType": "STORY",
        "title": "Why Eli Lilly Stock Just Popped",
        "description": "",
        "summary": "Eli Lilly has some good news for investors today. Novo Nordisk has some bad news (which is also good news for Lilly).",
        "pubDate": "2026-02-23T16:15:40Z",
        "displayTime": "2026-02-23T16:15:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/592d8d4e76e03021201e00455b5ee5fb",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "Woman injecting self in arm with a GLP-1 injector pen.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iVABqu0W2EYyD2OTb9hsTA--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/592d8d4e76e03021201e00455b5ee5fb.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pzab1GKpnfAGf2Mo2eEb6A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/592d8d4e76e03021201e00455b5ee5fb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/23/why-eli-lilly-stock-just-popped/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-eli-lilly-stock-just-161540738.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "INTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T16:10:51+00:00",
    "headline": "Novo Nordisk Sinks, Lilly Surges After Obesity Drug Trial Shock",
    "summary": "Novo Nordisk Stock Slides After CagriSema Disappoints in Late-Stage Study",
    "url": "https://finance.yahoo.com/news/novo-nordisk-sinks-lilly-surges-161051308.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "9f4f248f-36a0-3caa-bdf2-928bc7ddcb61",
      "content": {
        "id": "9f4f248f-36a0-3caa-bdf2-928bc7ddcb61",
        "contentType": "STORY",
        "title": "Novo Nordisk Sinks, Lilly Surges After Obesity Drug Trial Shock",
        "description": "",
        "summary": "Novo Nordisk Stock Slides After CagriSema Disappoints in Late-Stage Study",
        "pubDate": "2026-02-23T16:10:51Z",
        "displayTime": "2026-02-23T16:10:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-sinks-lilly-surges-161051308.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-sinks-lilly-surges-161051308.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T15:51:24+00:00",
    "headline": "Why Novo Nordisk Stock Just Crashed",
    "summary": "GLP-1 weight loss drug CagriSema may not be the salvation Novo Nordisk was hoping for.",
    "url": "https://www.fool.com/investing/2026/02/23/why-novo-nordisk-stock-just-crashed/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "6491744c-3000-3312-a7ac-0609931d2334",
      "content": {
        "id": "6491744c-3000-3312-a7ac-0609931d2334",
        "contentType": "STORY",
        "title": "Why Novo Nordisk Stock Just Crashed",
        "description": "",
        "summary": "GLP-1 weight loss drug CagriSema may not be the salvation Novo Nordisk was hoping for.",
        "pubDate": "2026-02-23T15:51:24Z",
        "displayTime": "2026-02-23T15:51:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/63da39fd621e94abb6624ad96f58663d",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "GLP-1 Semaglutide injector pens in a box.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YeqceUsyoZQr9sNviqDXCw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/63da39fd621e94abb6624ad96f58663d.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hzxTv57Pdx7MnqHTcbL0jA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/63da39fd621e94abb6624ad96f58663d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/23/why-novo-nordisk-stock-just-crashed/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-novo-nordisk-stock-just-155124895.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T15:50:00+00:00",
    "headline": "Eli Lilly: The Weight‚ÄëLoss and Diabetes Powerhouse I'd Hold Through Any Market Crash",
    "summary": "The stock looks unstoppable.",
    "url": "https://www.fool.com/investing/2026/02/23/eli-lilly-the-weight-loss-powerhouse-id-hold/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "42bccf66-7075-3ef6-aef8-f1029b68cc18",
      "content": {
        "id": "42bccf66-7075-3ef6-aef8-f1029b68cc18",
        "contentType": "STORY",
        "title": "Eli Lilly: The Weight‚ÄëLoss and Diabetes Powerhouse I'd Hold Through Any Market Crash",
        "description": "",
        "summary": "The stock looks unstoppable.",
        "pubDate": "2026-02-23T15:50:00Z",
        "displayTime": "2026-02-23T15:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/25b0e3db14b43d53726443021cae478a",
          "originalWidth": 1400,
          "originalHeight": 934,
          "caption": "Patient self-administering an injector pen.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mvcQ1_uFMeInm9mut.9ZhQ--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/25b0e3db14b43d53726443021cae478a.cf.webp",
              "width": 1400,
              "height": 934,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JAUNS.CnUhB0uaLH.S1Vqw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/25b0e3db14b43d53726443021cae478a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/23/eli-lilly-the-weight-loss-powerhouse-id-hold/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-weight-loss-diabetes-155000029.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T15:47:00+00:00",
    "headline": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Lilly, Arcellx, American Airlines, Strategy, Domino‚Äôs, Packaging Corp., and More",
    "summary": "Novo Nordisk stock sinks after new trial data show weight-loss drug candidate CagriSema is less effective than a rival treatment from Eli Lilly.",
    "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
      "content": {
        "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
        "contentType": "STORY",
        "title": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Lilly, Arcellx, American Airlines, Strategy, Domino‚Äôs, Packaging Corp., and More",
        "description": "",
        "summary": "Novo Nordisk stock sinks after new trial data show weight-loss drug candidate CagriSema is less effective than a rival treatment from Eli Lilly.",
        "pubDate": "2026-02-23T15:47:00Z",
        "displayTime": "2026-02-23T15:47:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f7d77d0b-860e-34ff-a495-c3fdff8b2514/these-stocks-are-today%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YpTBpBgno7NJFmEn4fooOg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SCGkZGeqjG9WPS36b0yD8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "STRC"
            },
            {
              "symbol": "STRD"
            },
            {
              "symbol": "STRF"
            },
            {
              "symbol": "STRK"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PKG"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "MSTR"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "JBLU"
            },
            {
              "symbol": "DAL"
            },
            {
              "symbol": "SW"
            },
            {
              "symbol": "IP"
            },
            {
              "symbol": "ALK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T15:18:00+00:00",
    "headline": "Why Novo Nordisk Stock Is Plunging‚Äîand Why It‚Äôs Good News for Lilly",
    "summary": "Novo shares slump after the Danish drugmaker‚Äôs experimental obesity drug fails to beat Lilly‚Äôs treatment in an 84-week trial.",
    "url": "https://www.barrons.com/articles/novo-nordisk-stock-price-eli-lilly-drug-trial-8715ba80?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "ade99e02-f1c5-3f9a-9d80-378a146f1a58",
      "content": {
        "id": "ade99e02-f1c5-3f9a-9d80-378a146f1a58",
        "contentType": "STORY",
        "title": "Why Novo Nordisk Stock Is Plunging‚Äîand Why It‚Äôs Good News for Lilly",
        "description": "",
        "summary": "Novo shares slump after the Danish drugmaker‚Äôs experimental obesity drug fails to beat Lilly‚Äôs treatment in an 84-week trial.",
        "pubDate": "2026-02-23T15:18:00Z",
        "displayTime": "2026-02-23T15:18:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ade99e02-f1c5-3f9a-9d80-378a146f1a58/why-novo-nordisk-stock-is.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/26KOn6oaSzam4fyehZ4clw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/phkijlebsiYXfKV4N8Qtzw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/3985777ea4a8bee88d7fbde151eccb25.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-stock-price-eli-lilly-drug-trial-8715ba80?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:46:00+00:00",
    "headline": "Zacks Market Edge Highlights: MasTec, Caterpillar, Walmart, Eli Lilly and Howmet Aerospace",
    "summary": "MasTec, Caterpillar, Walmart, Eli Lilly and Howmet Aerospace hit 5-year highs as double-digit 2026 earnings growth fuels a new \"Magnificent\" list.",
    "url": "https://finance.yahoo.com/news/zacks-market-edge-highlights-mastec-144600938.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "001fed99-af3f-38d8-bf34-2e37eeef375a",
      "content": {
        "id": "001fed99-af3f-38d8-bf34-2e37eeef375a",
        "contentType": "STORY",
        "title": "Zacks Market Edge Highlights: MasTec, Caterpillar, Walmart, Eli Lilly and Howmet Aerospace",
        "description": "",
        "summary": "MasTec, Caterpillar, Walmart, Eli Lilly and Howmet Aerospace hit 5-year highs as double-digit 2026 earnings growth fuels a new \"Magnificent\" list.",
        "pubDate": "2026-02-23T14:46:00Z",
        "displayTime": "2026-02-23T14:46:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/3d76cb528670a51f2c5ec1e11cfb6cdb",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BmCFfbDuZLdBtIMkVFr5BQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d76cb528670a51f2c5ec1e11cfb6cdb.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5qb0jADCn4EWNS9hfwqFrw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d76cb528670a51f2c5ec1e11cfb6cdb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zacks-market-edge-highlights-mastec-144600938.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zacks-market-edge-highlights-mastec-144600938.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BRK-B"
            },
            {
              "symbol": "MTZ"
            },
            {
              "symbol": "CAT"
            },
            {
              "symbol": "WMT"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "HWM"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "BAC"
            },
            {
              "symbol": "UNP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:41:07+00:00",
    "headline": "Stocks to Watch Monday: Merck, Novo Nordisk, Eli Lilly, Gilead",
    "summary": "üîé Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. ‚ÜòÔ∏è Novo Nordisk (NVO), (DK:NOVO.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
      "content": {
        "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Merck, Novo Nordisk, Eli Lilly, Gilead",
        "description": "",
        "summary": "üîé Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. ‚ÜòÔ∏è Novo Nordisk (NVO), (DK:NOVO.",
        "pubDate": "2026-02-23T14:41:07Z",
        "displayTime": "2026-02-23T14:41:07Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cb781f9d-b9a5-3f5a-bfb4-b439b3b47382/stocks-to-watch-monday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
          "originalWidth": 1200,
          "originalHeight": 630,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AC.ajdS9OghfMNW3mzlvpg--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 1200,
              "height": 630,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J5JxVR9DmLuomtxdXBS7Uw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PSKY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "FBIN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]